Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.56 |
| ▸ | SLC1A1 | P43005 | 5/20 | 0.52 |
| ▸ | SLC1A3 | P43003 | 5/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 5/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.48 |
| ▸ | GRIK1 | P39086 | 4/20 | 0.46 |
| ▸ | GRIK2 | Q13002 | 4/20 | 0.46 |
| ▸ | GGT1 | P19440 | 2/20 | 0.46 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.46 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL393346 | 1.00 | SLC7A5 (0.56) | SLC7A5SLC1A1SLC1A3SLC1A2PTGS1 | |
| SCHEMBL4254400 | 1.00 | SLC7A5 (0.56) | SLC7A5SLC1A1SLC1A3SLC1A2PTGS1 | |
| SCHEMBL4947418 | 1.00 | SLC7A5 (0.56) | SLC7A5SLC1A1SLC1A3SLC1A2PTGS1 | |
| SCHEMBL5819946 | 1.00 | SLC7A5 (0.56) | SLC7A5SLC1A1SLC1A3SLC1A2PTGS1 | |
| SCHEMBL5823952 | 1.00 | SLC7A5 (0.56) | SLC7A5SLC1A1SLC1A3SLC1A2PTGS1 | |
| SCHEMBL13746293 | 1.00 | SLC7A5 (0.56) | SLC7A5SLC1A1SLC1A3SLC1A2PTGS1 | |
| SCHEMBL196983 | 1.00 | SLC7A5 (0.56) | SLC7A5SLC1A1SLC1A3SLC1A2PTGS1 | |
| SCHEMBL305904 | 1.00 | SLC7A5 (0.56) | SLC7A5SLC1A1SLC1A3SLC1A2PTGS1 | |
| SCHEMBL13753646 | 1.00 | SLC7A5 (0.56) | SLC7A5SLC1A1SLC1A3SLC1A2PTGS1 | |
| SCHEMBL3744052 | 0.84 | OR51E2 (0.42) | SLC7A5SLC1A1SLC1A3SLC1A2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4181781-B1 | BREATH-BASED THERAPEUTIC DRUG MONITORING METHOD | UNIV KINDERSPITAL BEIDER BASEL (CH) | 2026-05-20 | — | — | EP | disclosed |
| EP-4541812-A2 | GENERATION OF A HIGH PRODUCING RECOMBINANT CHINESE HAMSTER OVARY CELL LINE FOR THERAPEUTIC PROTEIN PRODUCTION | Sanofi (FR) | 2025-04-23 | — | — | EP | disclosed |
| EP-4214308-B1 | GENERATION OF A HIGH PRODUCING RECOMBINANT CHINESE HAMSTER OVARY CELL LINE FOR THERAPEUTIC PROTEIN PRODUCTION | SANOFI SA (FR) | 2024-11-20 | — | — | EP | disclosed |
| EP-4419094-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS | Edison Oncology (US) | 2024-08-28 | — | — | EP | disclosed |
| US-20240043878-A1 | GENERATION OF A HIGH PRODUCING RECOMBINANT CHINESE HAMSTER OVARY CELL LINE FOR THERAPEUTIC PROTEIN PRODUCTION | SANOFI (FR) | 2024-02-08 | — | — | US | disclosed |
| US-20230277125-A1 | BREATH-BASED THERAPEUTIC DRUG MONITORING METHOD | UNIVERSITÄTS-KINDERSPITAL BEIDER BASEL (CH) | 2023-09-07 | — | — | US | disclosed |
| EP-4214308-A1 | GENERATION OF A HIGH PRODUCING RECOMBINANT CHINESE HAMSTER OVARY CELL LINE FOR THERAPEUTIC PROTEIN PRODUCTION | Sanofi (FR) | 2023-07-26 | — | — | EP | disclosed |
| CN-116457468-A | Production of high-yielding recombinant chinese hamster ovary cell lines for therapeutic protein production | 赛诺菲 | 2023-07-18 | — | — | CN | disclosed |
| US-20230212549-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2023-07-06 | — | — | US | disclosed |
| US-20230212549-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2023-07-06 | — | — | US | disclosed |
| US-7811804-B2 | synthetic or recombinant polypeptide having a nitrilase activity; have increased activity and stability at increased pH and temperature | VERENIUM CORPORATION (US) | 2010-10-12 | — | — | US | disclosed |
| US-20100086986-A1 | Increased activity and stability at increased pH and temperature; making a chiral alpha -hydroxy acid molecule, a chiral amino acid molecule, a chiral beta -hydroxy acid molecule, or a chiral gamma-hydroxy acid molecule, from a molecule with a cyanohydrin moiety or an aminonitrile moiety | VERENIUM CORPORATION (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100086986-A1 | Increased activity and stability at increased pH and temperature; making a chiral alpha -hydroxy acid molecule, a chiral amino acid molecule, a chiral beta -hydroxy acid molecule, or a chiral gamma-hydroxy acid molecule, from a molecule with a cyanohydrin moiety or an aminonitrile moiety | VERENIUM CORPORATION (US) | 2010-04-08 | — | — | US | disclosed |
| US-7651849-B2 | Increased activity and stability at increased pH and temperature | VERENIUM CORPORATION | 2010-01-26 | — | — | US | disclosed |
| US-7651849-B2 | Increased activity and stability at increased pH and temperature | VERENIUM CORPORATION | 2010-01-26 | — | — | US | disclosed |
| US-20100009426-A1 | synthetic or recombinant polypeptide having a nitrilase activity; have increased activity and stability at increased pH and temperature | VERENIUM CORPORATION (US) | 2010-01-14 | — | — | US | disclosed |
| US-20090176976-A1 | Increased activity and stability at increased pH and temperature | VERENIUM CORPORATION | 2009-07-09 | — | — | US | disclosed |
| US-20090176976-A1 | Increased activity and stability at increased pH and temperature | VERENIUM CORPORATION | 2009-07-09 | — | — | US | disclosed |
| US-7521216-B2 | Nitrilases and methods for making and using them | VERENIUM CORPORATION (US) | 2009-04-21 | — | — | US | disclosed |
| EP-2039762-A2 | Nitralases | Verenium Corporation (US) | 2009-03-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212549-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | FIBP, FN1, TPX2 | SLC7A5 3294/4885SLC1A1 3353/4885SLC1A3 3634/4885 |
| US-20100086986-A1 | Increased activity and stability at increased pH and temperature; making a chiral alpha -hydroxy acid molecule, a chiral amino acid molecule, a chiral beta -hydroxy acid molecule, or a chiral gamma-hydroxy acid molecule, from a molecule with a cyanohydrin moiety or an aminonitrile moiety | ASPH, AHSA1, DNPH1 | SLC7A5 837/4885SLC1A1 1223/4885SLC1A3 1415/4885 |
| US-20240043878-A1 | GENERATION OF A HIGH PRODUCING RECOMBINANT CHINESE HAMSTER OVARY CELL LINE FOR THERAPEUTIC PROTEIN PRODUCTION | DHODH, GLUL, GLS2 | SLC7A5 434/4885SLC1A1 956/4885SLC1A3 825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.